Polyvalent Cation Composition for Drug Retention in Bloodstream
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack effective methods to control pharmacokinetics, particularly the metabolism and excretion of drugs by liver sinusoidal endothelial cells and kidneys, which affect drug distribution and concentration in the body.
Innovation Solution
A composition comprising polyvalent cations, such as cationic polymers modified with polyethylene glycol, is administered to localize on the inner vascular surfaces of liver sinusoidal endothelial cells and kidney vascular endothelium, reducing their ability to excrete drugs and enhancing drug retention in the bloodstream.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs are administered to achieve therapeutic effects, then the concentration of drug in blood is improved, but the drug is rapidly metabolized and excreted by liver sinusoidal endothelial cells and kidneys, reducing duration of action
Solution Approach 1:
The patent introduces polyvalent cations as intermediary substances that adsorb onto the surface of liver sinusoidal endothelial cells and kidneys. These cations act as mediators that block the direct interaction between drugs and excretory pathways, thereby extending drug retention time in blood without altering the drug's core structure or therapeutic mechanism
Solution Approach 2:
The patent changes the physical-chemical parameters of the biological system by introducing charged cationic polymers that modify the surface properties of endothelial cells. This parameter change (surface charge density) prevents drug adsorption and excretion, thereby extending the duration of drug action while maintaining therapeutic concentration
2Productivity
If drugs are excreted by liver sinusoidal endothelial cells and kidneys to eliminate toxins, then clearance function is improved, but therapeutic drug concentration is reduced, affecting reliability
Solution Approach 1:
Polyvalent cations serve as intermediary substances that selectively block drug excretion pathways without interfering with the physiological clearance function. The cations adsorb onto cell surfaces and prevent drug-membrane interaction, allowing the clearance system to remain functional while retaining therapeutic drugs in circulation
3Reliability
If polyion complexes are used to enhance drug stability, then drug protection is improved, but complex formation may increase device complexity or administration difficulty
Solution Approach 1:
The patent applies local quality modification by introducing polyvalent cations specifically at the interface between blood and excretory organs (liver and kidney surfaces). This localized approach provides drug protection exactly where excretion occurs, without requiring complex systemic modifications or elaborate delivery systems throughout the entire body
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses drug metabolism and excretion, increases drug delivery to target organs like the spleen, and improves the retention of drugs in the bloodstream by reducing the clearance function of endothelial cells.
Implementation Method 1
polyvalent cations (especially, polyvalent cations modified with polyethylene glycol to enhance their biocompatibility) are localized on the inner vascular surface of the liver sinusoidal endothelial cells and the inner vascular surface of the vascular endothelium of the kidneys
Data Source
Figure 1
Figure 2~2A
Figure 3
AI summary
The present invention provides a composition that controls pharmacokinetics. Specifically, the present invention provides: a composition for controlling pharmacokinetics, the composition containing a polyvalent cation as an active ingredient; and a method for controlling pharmacokinetics using the polyvalent cation.